Cargando…

Lenalidomide in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults. Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options clearly indicate that new agents or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thieblemont, Catherine, Delfau-Larue, Marie-Hélène, Coiffier, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508519/ https://www.ncbi.nlm.nih.gov/pubmed/23251161 http://dx.doi.org/10.1155/2012/861060

Ejemplares similares

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions
por: Karlin, Lionel, et al.
Publicado: (2013)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment
por: Ma, Li-Yangxue, et al.
Publicado: (2018)

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
por: Desai, Madhav, et al.
Publicado: (2013)

Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials
por: Liu, Jia, et al.
Publicado: (2022)

Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
por: Wang, Xiaoyan, et al.
Publicado: (2023)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
por: Al Dhafiri, Mahdi, et al.
Publicado: (2019)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
por: Chiu, Hsiling, et al.
Publicado: (2019)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells
por: Nuan-Aliman, Stéphanie, et al.
Publicado: (2022)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma
por: Reddy, Nishitha M., et al.
Publicado: (2016)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Treatment of Diffuse Large B Cell Lymphoma
por: Kwak, Jae-Yong
Publicado: (2012)

Genomics of diffuse large B cell lymphoma
por: Koh, Youngil
Publicado: (2021)

Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report
por: Hu, Pan, et al.
Publicado: (2021)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

Inflammatory Cells in Diffuse Large B Cell Lymphoma
por: Tamma, Roberto, et al.
Publicado: (2020)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses
por: Broséus, Julien, et al.
Publicado: (2016)

ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma
por: Auguste, Tiphanie, et al.
Publicado: (2013)

P1224: PATIENT-DERIVED XENOGRAFT (PDX) IS A USEFUL TOOL FOR EVALUATING 5-AZACYTIDINE SENSITIVITY IN TFH LYMPHOMAS
por: Tari, Gamze, et al.
Publicado: (2023)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma in the HIV Setting
por: Huguet, Maria, et al.
Publicado: (2023)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022)

Germline mutations predisposing to diffuse large B-cell lymphoma
por: Leeksma, O C, et al.
Publicado: (2017)

New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0sra5cm8c8p2hjr1slrl5j1uak